Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
rees> Brazil Minerals has now direct ownership of projects in a triad of strategic minerals - lithium, titanium, and rare earths.
"Lithium is in high demand worldwide and Brazilian lithium reserves are now recognized as some of the best in yield and purity upon processing. Our lithium project holds high potential, and we look forward to its continued development."
97,958 acres of some best gold areas of brazil
they are out of shares to dilute,want to raise o/s
hello congrats on GAXY take a look into RIII .05 38M float with Kevin Harrington of shark tank on the board of directors and very much involved. CEO says working on something that will dwarf the numbers shareholders know [which is inventory 3x its market cap) .. 5G stock
I don't know but these two companies were both substantial companies even before this merger.. I'm hoping for something BIG!~
How much better could it possibly get after a 1:12 reverse split?
What's to expect on conference call next Tues? Should we be nervous? Or are good things coming? Possibly the announcement of a virus dermatological absorption ointment/solution? Anyone? Help.
Anybody get TMBR on the drop ? It's headed back up fast!
And I[m not one to tell other people what to do, but the before prices and news and out look for the future is pretty good all things considered. Just my opinion.
Too good of a stock to be selling this cheap.. Had a market scare that's all.. Once this market stabalizes there's money to be made here. Look at the pre-crash trading price. Market scare that's all.. I'm in and staying for a while.
Yea, it'll be interesting to see what happens tomorrow. The two companies together are worth over 20 Million. What will be the amount of shares available for the new TMBR? BPMX has 18.28 Million divided by 12, which is just over 1.5M. Certainly the outstanding can't be that low for TMBR shares tomorrow. The value would be over $14 share.
Closing in on .52 real fast..~
It's back over .50..
Does anyone know if it is true or potentially true that BPMX post RM, is going to announce a dermatological subcutaneous absorption product for phase 1 approval for battling CV19?
Anybody get in on the bounce.. It's leaving the building RIGHT NOW!
Bounce coming!
Cheap as it's going to get any time soon. Prepare for another run..
Notice how they evened that out to .50 right after hours so they could do their 12 X 1 trade without any fractional share complications?
Only wish I had bought a lot more earlier today
Thanks. What would be the starting price after r/s?
Yes you will get shares of TMBR. but and it's a big but they approved a 1:5 or 1:25 reverse stock split. The play on this one would be after the close because they are looking to drive the pps up fast with the reverse split which would give TMBR a micro float once the price is up they will probably do a market offering at some point.
Always do your dd.
you still in $cbdl
* * $BPMX Video Chart 05-14-2020 * *
Link to Video - click here to watch the technical chart video
After the merger, do we get shares from tmbr?
Priced in. Zero shorts. Nothing to move it really...
Check dcar another reverse merger play will double low float only 3 m shares new ceo will be x Segway ceo electric car company
Massive shorts here will cover fuels the run soon.
Merge done here stock on fire bro.
Aye aye, grabbed some more
$BPMX This merge will move bpmx above one dollar
MERGE NEWS!
BioPharmX Corporation Announces Approval of Merger by Stockholders at Special Meeting
PR Newswire PR Newswire•May 13, 2020
CAMPBELL, Calif., May 13, 2020 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) ("BioPharmX") today announced that all proposals related to its proposed merger with Timber Pharmaceuticals LLC ("Timber") were approved by BioPharmX's stockholders at a special meeting held on May 13, 2020. The proposed merger remains subject to further customary closing conditions and regulatory approvals. BioPharmX and Timber expect the closing of the merger to occur on or about May 18, 2020.
(PRNewsfoto/BioPharmX Corporation)
(PRNewsfoto/BioPharmX Corporation)
More
Upon closing of the transaction, the combined company will change its name to "Timber Pharmaceuticals, Inc." and it is anticipated that the shares will commence trading on the NYSE American market under the ticker symbol "TMBR." The officers and managers of Timber will assume leadership of the combined company with Michael Derby serving as Chairman and John Koconis as Chief Executive Officer.
Timber is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The combined company will have a robust pipeline including Timber's two Phase 2b programs and a preclinical program targeting multiple niche orphan indications with no approved treatments as well as BioPharmX's two Phase 3-ready topical minocycline programs. Following the closing of the merger, the combined company will evaluate BioPharmX's Phase 3-ready programs for a strategic partnership, co-development, or other non-dilutive value creation opportunities.
The final voting results for BioPharmX's special meeting of stockholders will be filed with the Securities and Exchange Commission (the "SEC") in a Form 8-K.
Where to find additional information about the Special Stockholders Meeting, the proposed merger and related matters
On February 20, 2020, BioPharmX filed a Registration Statement on Form S-4 with the SEC containing a prospectus and a proxy statement of BioPharmX concerning the proposed merger between BioPharmX and Timber. The registration statement was declared effective by the SEC on March 30, 2020 and the proxy statement describing the merger and related matters was mailed to BioPharmX stockholders on or about April 6, 2020. Subsequently, on April 27, 2020, BioPharmX filed a supplement to its proxy statement describing certain changes to the terms of the merger and related matters from that described in the original proxy statement. The supplement was mailed to BioPharmX stockholders on or about April 28, 2020.
INVESTORS AND SECURITY HOLDERS OF BIOPHARMX ARE URGED TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT BIOPHARMX, TIMBER, THE MERGER, AND RELATED MATTERS.
The proxy statement/prospectus, the supplement, and any other documents filed by BioPharmX with the SEC, may be obtained free of charge at the SEC website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with the SEC by BioPharmX by directing a written request to: BioPharmX Corporation, 900 E. Hamilton Avenue, Suite 100, Campbell, CA 95008 or by downloading the materials from the Investor Page of the BioPharmX website, www.BioPharmX.com.
Continue reading
They vote today so something must be good!
$BPMX break this wall at 52 we got a lil run on our hands to 60
* * $BPMX Video Chart 05-11-2020 * *
Link to Video - click here to watch the technical chart video
what news? you mean the news that they want to do another reverse split after they merge with Timber?
Seems it’s gonna run end of day type stock I would not short this here with the news
Followers
|
102
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3061
|
Created
|
02/04/13
|
Type
|
Free
|
Moderators |
In dermatology, for example, we are developing a unique way to deliver acne-fighting medicine topically. Today’s most effective acne medications must be ingested, risking undesirable side-effects. Topical treatments tend to be ineffective because their formulations do not deliver medication to the layer of skin where acne forms. Our developmental topical, called BPX-01, effectively delivers small amounts of antibiotic to the acne source, maximizing treatment effectiveness and reducing side-effects.
In women’s health, we are currently focused on improving breast health by treating fibrocystic breast condition, a medical problem that affects half the world’s women. The condition, which often produces breast tenderness and tissue density, can be treated with molecular iodine, which is effective but rarely found in a stable form. Our solution is Violet® iodine, a daily supplement that produces molecular iodine within the body – exactly where it can be most effective.
Both of these solutions demonstrate the power of BioPharmX’s unique combination of innovation and determination.
Currently in phase 2 of clinical development, BPX-01 may offer a breakthrough in acne treatment because it can deliver the antibiotic to the area of the skin where acne develops. The novel hydrophilic (non oil-based) formulation of minocycline may be more effective than other topical alternatives because they either use less effective antibiotics to penetrate the top layer of the skin or rely on higher concentrations of minocycline, which could lead to unpleasant side effects.
BPX-01 is the first and only stable hydrophilic topical gel with fully solubilized minocycline. Minocycline, an antibacterial and anti-inflammatory medicine, is the most commonly prescribed acne treatment because it has a lower resistance rate than other antibiotics. No stable form of hydrophilic topical minocycline is currently commercially available.
http://www.biopharmx.com/products/#dermatology
Morlock previously served as executive vice president and chief financial officer from 1994 to 2004 at Otis Spunkmeyer, a baked goods distribution company that has successfully pursued distribution of its products to small family-owned businesses all the way up to large worldwide organizations, including the U.S. Army. He served as controller there from 1992 to 1994. He also has experience garnered from these roles in various aspects of the retail industry, including going to market via various distribution channels, product merchandizing, customer relationship management, brand development, manufacturing, procurement, and inventory management.
"Stephen brings a unique blend of financial expertise and experience in the retail industry to BioPharmX," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX Corporation. "His expertise and experience will prove valuable as we continue retail distribution expansion for Violet iodine."
Prior to his roles at Otis Spunkmeyer, Morlock held various management positions in accounting, financial planning and internal auditing at Westinghouse Electric Supply Company from 1977 to 1991. He holds a B.S. degree in Accounting from San Diego State University
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |